Anti-psychotic drugs cause brain damage.

Reading list: Chemical imbalances are bogus and mythical by Loren R. Mosher M.D.

Click to View

The Biopsychiatric Model
of "Mental Illness"

"A Critical Bibliography" by Loren R. Mosher M.D.

"Conclusion: the brain abnormalities attributed causal significance in mental illness are most likely the result of neuroleptic drug treatment." (Loren R. Mosher M.D.)

See also: Psychiatrist Loren Mosher resigns from the American Psychiatric Association (APA) because of bogus scientific claims related to chemical imbalances and corrupt support of the drug companies to perpetuate this myth.

Dr Mosher writes:

"Presented below is an annotated bibliography addressing today's widely held belief system about the causes and treatment of disturbed and disturbing behavior usually labeled as some form of serious mental illness. As "schizophrenia" is psychiatry's most vexing and perplexing "disorder" and viewed as the most serious of the "mental illnesses" it is the primary focus of this list. It excludes children. It is not exhaustive, but is representative." (Loren R. Mosher M.D.)

Dr Mosher's Conclusions:

"Today's dominant theory of serious" mental illnesses" posits them to be genetically determined (i.e., inherited), biochemically mediated (via "chemical imbalances"), life-long" brain diseases"(with associated specific neuropathologic changes) whose cause(s) and course is more or less independent of environmental factors is not supported by existing evidence. A critical review of the scientific available evidence reveals no clear indication of hereditary factors, no specific biochemical abnormalities, and no associated causal neurologic lesion(s). However, a number of environmental factors have been found to be related to their cause(s) and course(bibliography in preparation). It is also generally held that the anti-psychotic drugs are the mainstay of treatment and should, in most cases, be taken for a lifetime. In fact, the data indicate that neuroleptic drug treatment is not usually necessary (especially in persons newly identified as psychotic) if a proper interpersonal environment and social context is provided in alternatives to hospital care. It also appears that has drug treatment has resulted in less favorable long-term outcomes than was the case before anti-psychotic drugs were introduced. Furthermore, anti-psychotic drug treatment is associated with the induction of irreversible brain pathology (resulting in reduced intellectual and abnormal motor functioning) and shortened life expectancy. Pre-neuroleptic drug era long-term follow-up studies indicate that recovery can not only occur, but is to be expected in the majority of cases. Ergo, so called "chronicity" in "mental illness" is likely the result of its medicalization, institutionalization with its social network disruption, marginalization, discrimination and the less specific social consequences (e.g. poverty) that accompany these processes." (Loren R. Mosher M.D.)

Click to View

Brain Damage Associated with Neuroleptic Drug Treatment:

(tranquilizers used to treat psychotic conditions when a calming effect is desired)

"Conclusion: the brain abnormalities attributed causal significance in mental illness are most likely the result of neuroleptic drug treatment." (Loren R. Mosher M.D.)

Reading list: Anti-psychotic drugs cause brain damage:

"Conclusion: the brain abnormalities attributed causal significance in mental illness are most likely the result of neuroleptic drug treatment." (Loren R. Mosher M.D.)

  1. Ballesteros J, Gonzales-Pinto A, & Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacology, 20:2, 188-194, 2000.
  2. E Christensen. "Neuropathological investigations of 28 brains from patients with dyskinesia." Acta Psychiatrica Scandinavica, 46,14-23, 1970. (TD patients have structural abnormalities in the basal ganglia, enlarged ventricles, and sulcal markings.)
  3. OO Famuyiva. Tardive dyskinesia and dementia. British Journal of Psychiatry, 135, 500-504, 1979. (TD associated with cognitive impairment.)
  4. JT Wegner. Cognitive impairment in tardive dyskinesia. Psychiatry Research, 16, 331-337. 1985. (TD associated with cognitive impairment.)
  5. James Wade. Tardive Dyskinesia and Cognitive Impairment. Biological Psychiatry, 22, 393-395, 1987. (Association between TD and cognitive impairment. "The relationship appears to be linear: individuals with severe forms of the disorder are most impaired cognitively.")
  6. JL Waddington. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Archives of General Psychiatry, 44, 907-912, 1987. (TD associated with cognitive impairment and worsening of negative symptoms.)
  7. Waddington J et al, Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study, Br J Psych, 1998, 173; 325-329. (This study found that a reason that schizophrenics have a shorter life expectancy was neuroleptic drug treatment)
  8. JB Wade. Cognitive changes associated with tardive dyskinesia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology. 1, 217-227. 1989. (TD associated with cognitive impairment. The researchers conclude: "TD may represent both a motor and dementing disorder.")
  9. R. Yassa. Functional impairment in tardive dyskinesia: medical and psychosocial dimensions. Acta Psychiatr Scand 80, 64-67. 1989. (TD associated with gait, speech difficulties, and psychosocial impairment.)
  10. Michael S. Myslobodsky. Central Determinants of Attention and Mood Disorder in Tardive Dyskinesia (Tardive Dysmentia.). Brain and Cognition, 23, 88-101. 1993. (TD patients lose the motor part of their "road map of consciousness." TD may represent "larval dementia.")
  11. Herbert Spohn. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizoprhenics." Brain and Cognition 23, 28-39, 1993. (TD exacerbates cognitive impairment.)
  12. Jacinthe Baribeau. Tardive dyskinesia and associated cognitive disorders: a convergent neuropsycological and neurophysiological approach. Brain and Cognition 23, 40-55, 1993. (TD associated with cognitive dysfunction.)
  13. John Waddington. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain and Cognition 23, 56-70, 1993. (He reviews 22 studies from 1979 to 1991 that concluded that patients with TD were cognitively impaired on a variety of measures, which include learning, memory, cognitive function, intellectual function, visual retention, orientation, etc.)
  14. James Wade. Factors related to the severity of tardive dyskinesia. Brain and Cognition 23, 71-80, 1993. (A review of research shows that "biochemical and neuropathological changes associated with TD indicates that similar alterations are associated with Hungtington's disease and or Parkinson's." In their own research, "cortical dysfunction, characterized by impairment in nonverbal function, is associated with TD severity.")
  15. Emmanuelle Pourcher. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia. Brain and Cognition 23, 81-87, 1993. (This is a study of patients under 40. They find that TD is associated with cerebral dysfunction, which in turn is associated with exposure to neuroleptic drugs.)
  16. Thomas Gualtieri. The problem of tardive akathisia. Brain and Cognition 23, 102-109, 1993. (He states that tardive akathisia may be thought of as a disease of the basal ganglia, much like Parkinson's, Huntington's and Wilson's. MRI studies have demonstrated basal ganglia lesions in TD patients, especially in the caudate nucleus. Basal ganglia diseases all cause behavioral instability and intellectual impairment (even psychosis and dementia)).
  17. Miranda Chakos. Increase in Caudate Nuclei Volumes of First-Episode Schizophrenic Patients Taking Antipsychotic Drugs. Am Jour Psych 151, 1430-1435. 1994. (Neuroleptics increase caudate volumes 5.7% during first 18 months of treatment in first-episode schizophrenic patients. Higher dosage is associated with larger increase in caudate volumes.)
  18. J.S. Paulsen. Neuropsychological impairment in tardive dyskinesia. Neurospsychology 8, 227-241. 1994. (Review of 31 studies that compared cognitive function in schizophrenics with and without TD. In 24 studies, TD patients were found to do worse. The more severe the TD, the greater the impairment in cognitive function. They conclude that "TD involves an alteration of brain function that affects both motor and cognitive control.")
  19. P. Sachdev. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia." Acta Psychiatr Scand. 93, 451-459. 1996. (Both tardive akathisia and tardive dyskinesia are associated with more cognitive deficits and negative symptoms. This association is stronger with TA than with TD. The implication is that movement disorders seen in TA and TD are "but one feature of complex syndromes that include motor and cognitive features. A comparison must be made with other movement disorders, such as Parkinson's disease and Huntington's disease, in which neuropsychological deficits, and indeed subcortical dementia are known to occur.")
  20. John Waddington. Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine, 26, 681-688. 1996. (Progressive deterioration in cognitive function is seen even late in chronic phase of schizophrenic illness. Deterioration derives primarily from emergence of TD. They find that marked deterioration in cognitive function occurs at same time as emergence of movement disorder.)
  21. Rupert McShane. Do Neuroleptic Drugs Hasten Cognitive Decline in Dementia? Prospective Study with Necropsy Follow Up. British Medical Journal, 314, 266-270. 1997. (The decline in cognitive function in dementia patients who take neuroleptics is twice the decline in patients who did not take he drugs.)
  22. Raquel Gur,et. Al. Subcortical MRI Volumes in Neuroleptic-Naïve and Treated Patients with Schizophrenia. American Journal of Psychiatry, 155, 1711-1717. 1998. (Drugs cause hypertrophy of the caudate, putamen, and thalamus, which is thought to be "structural adaptation to receptor blockade." The drug-induced hypertrophy is also "mildly associated with greater severity of both negative and positive symptoms.")
  23. Raquel Gur, et. Al. A follow-up of magnetic resonance imaging study of schizophrenia. Archives of General Psychiatry, 55, 145-151, 1998. (Use of neuroleptics is associated with volume reduction (or atrophy) of frontal lobes and temporal lobes. As the brain atrophies in this way, here is said to improvement in delusions and thought disorder (the brain-damaging principle at work). A greater rate of reduction in volume is associated with higher dose. At the same time, reduction in volume is associated with decline in some neurobehavioral functions.)
  24. Al Madsen. Neuroleptics in progressive structural brain abnormalities in psychiatric illness. The Lancet, 352, 784-785. Sept. 5, 1998. (Neuroleptic use is associated with atrophy of cerebral cortex. The estimated risk of atrophy increases by 6.4% for each additional 10 grams of neuroleptic drug.)
  25. G. Tsai. Markers of glutamergic neurotransmission and oxidative stress associated with tardive dyskinesia. American Journal of Psychiatry, 155, 1207-1213. 1998. (This study suggests that neuroleptics cause neuronal damage as a result of oxidative stress, and that this is the degenerative process that produces TD.)

By Dr. Loren R. Mosher

By Steve Rudd: Contact the author for comments, input or corrections.

Send us your story about your experience with modern Psychiatry


Click to View